Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (221-230 of 283) with videos related to

Pageof 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 TrialEdward A Stadtmauer, Marcelo C Pasquini, Beth Blackwell, et al.
NPJ Genomic Medicine|January 26, 2023
Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myelomaWilliam Pilcher, Beena E Thomas, Swati S Bhasin, et al.
Leukemia & Lymphoma|July 7, 2020
Primary refractory multiple myeloma: a real-world experience with 85 casesArtur Jurczyszyn, Anna Waszczuk-Gajda, Jorge J Castillo, et al.
Blood Advances|February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in MyelomaWilliam A Wood, Shaji K Kumar, Emily Semmel, et al.
Nature Communications|November 28, 2020
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myelomaCinzia Federico, Kinan Alhallak, Jennifer Sun, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 29, 2021
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple MyelomaLuciano J Costa, Yi Lin, R Frank Cornell, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2021
POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter AnalysisArtur Jurczyszyn, Jorge J Castillo, Magdalena Olszewska-Szopa, et al.
Blood|May 5, 2012
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myelomaRavi Vij, Michael Wang, Jonathan L Kaufman, et al.
Nature Communications|February 2, 2018
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potentialTerrence N Wong, Christopher A Miller, Matthew R M Jotte, et al.
Leukemia & Lymphoma|March 28, 2015
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myelomaRuben Niesvizky, Ashraf Z Badros, Luciano J Costa, et al.
Pageof 29

Showing results (221-230 of 283) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 TrialEdward A Stadtmauer, Marcelo C Pasquini, Beth Blackwell, et al.
NPJ Genomic Medicine|January 26, 2023
Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myelomaWilliam Pilcher, Beena E Thomas, Swati S Bhasin, et al.
Leukemia & Lymphoma|July 7, 2020
Primary refractory multiple myeloma: a real-world experience with 85 casesArtur Jurczyszyn, Anna Waszczuk-Gajda, Jorge J Castillo, et al.
Blood Advances|February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in MyelomaWilliam A Wood, Shaji K Kumar, Emily Semmel, et al.
Nature Communications|November 28, 2020
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myelomaCinzia Federico, Kinan Alhallak, Jennifer Sun, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 29, 2021
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple MyelomaLuciano J Costa, Yi Lin, R Frank Cornell, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2021
POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter AnalysisArtur Jurczyszyn, Jorge J Castillo, Magdalena Olszewska-Szopa, et al.
Blood|May 5, 2012
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myelomaRavi Vij, Michael Wang, Jonathan L Kaufman, et al.
Nature Communications|February 2, 2018
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potentialTerrence N Wong, Christopher A Miller, Matthew R M Jotte, et al.
Leukemia & Lymphoma|March 28, 2015
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myelomaRuben Niesvizky, Ashraf Z Badros, Luciano J Costa, et al.
Pageof 29